查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1877452

CAR-T細胞療法市場：依產品類型、標靶抗原、適應症、最終用戶、國家及地區分類－全球產業分析、市場規模、市場佔有率及2025-2032年預測

CAR T-cell Therapy Market, By Product Type, By Target Antigen, By Indication, By End user, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 365 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年 CAR T 細胞療法市場規模價值為 56.78 億美元，從 2025 年到 2032 年將以 38.5% 的複合年成長率成長。

CAR-T細胞療法是一種利用基因工程改造的免疫細胞療法，它能修飾患者自身的T細胞，使其標靶並殺死癌細胞。該療法最初用於治療某些血液癌症，目前也擴大探索其在實體腫瘤治療中的應用。由於在復發或難治性血液系統惡性腫瘤中取得了顯著的臨床療效，加上研發管線的拓展、法規核准的增加以及生物製藥和特種細胞療法生產商投資的不斷成長，CAR-T細胞療法市場正迅速擴張。複雜的生產流程、對專業治療中心的需求以及高昂的治療費用構成了一定的挑戰，但生產規模的擴大、合作夥伴關係的建立以及新一代CAR-T細胞的設計正在推動其商業化進程。

CAR-T細胞療法市場－市場動態

臨床療效提高，緩解期持久

CAR-T細胞療法顯著提高了復發或難治性血液腫瘤患者的臨床療效，並實現了持久緩解。臨床試驗和真實世界應用的大量結果表明，該療法能夠在其他療法失敗的情況下產生長期療效，這促使醫生採用該療法，促使支付方承擔高昂的費用，並吸引了渴望拓展適應症和擴大生產規模的製藥公司和製造商的投資。

CAR-T細胞療法市場區隔分析：

全球 CAR T 細胞療法市場按產品類型、目標抗原、適應症、最終用戶和地區進行細分。

根據產品類型，市場分為七大類：Abecma、Breyanzi、Carvykti、Kymriah、Tecartus、Yescarta 和其他。目前，Kymriah 和 Yescarta 等成熟產品憑藉其更早累積的更廣泛的臨床經驗、已獲批准的藥品以及更大的商業涵蓋範圍，佔據市場主導地位。

標靶抗原市場又可細分為七類：CD19、BCMA（B細胞成熟抗原）、CD22、GD2、HER2、GPC3 和其他（例如 EGFRvIII、CD7、CD123、間皮素）。 CD19 目前仍是該領域的主導類別，這主要得益於其在 B 細胞白血病和淋巴瘤治療中取得的成功。 BCMA 是成長最快的類別，這主要歸功於其在多發性骨髓瘤治療中的顯著療效以及不斷湧現的新產品。

依適應症分類，共有四大類：急性淋巴性白血病、淋巴瘤、多發性骨髓瘤及套細胞淋巴瘤。由於多種BCMA CAR-T療法即將上市，多發性骨髓瘤在短期內最具成長潛力。實體瘤是最大的長期發展機遇，但面臨巨大的科學和轉化障礙，將延緩其商業化。血液系統惡性腫瘤（急性淋巴性白血病、各種淋巴瘤和多發性骨髓瘤）將繼續推動近期收入和市場普及，因為大多數核准藥物和臨床經驗都集中在這一領域。

最終使用者群體包括醫院和專門的癌症治療中心，這些是主要的治療場所，因為 CAR-T 療法需要專門的基礎設施、住院監測和多學科團隊；這些中心將佔據當前的大部分業務量。

CAR-T細胞療法市場—地域性洞察

北美，尤其是美國，是最大的市場，這得益於強勁的生物技術投資、完善的臨床試驗基礎設施和有利的報銷政策；歐洲緊隨其後，採用率不斷提高，但各國的報銷情況不盡相同；亞太地區是一個高成長地區，這得益於醫療保健支出的成長、中國、日本和韓國臨床能力的發展以及一些國家製造的價格

CAR-T細胞療法市場－競爭格局：

競爭格局由擁有已批准的 CAR-T 產品的大型生物技術/製藥公司和眾多開發下一代和同種異體療法的小型創新者和學術衍生公司主導；競爭的重點是臨床表現、安全性（減少細胞因子釋放症候群/神經毒性）、生產規模和成本以及生產和分銷的商業合作關係，併購、許可協議和戰略聯盟很常見，因為公司正在努力確保產品線。

目錄

第1章：CAR-T細胞療法市場概覽

  • 研究範圍
  • 市場估算年份

第2章：執行概要

  • 市集
    • CAR T 細胞療法市場按產品類型分類的概覽
    • CAR T 細胞療法市場概覽（以標靶抗原分類）
    • CAR-T細胞療法市場按適應症分類的概況
    • CAR T 細胞療法市場按最終用戶分類的概覽
    • 各國 CAR-T 細胞療法市場概況
    • CAR-T細胞療法市場概覽（按地區分類）
  • 競爭洞察

第3章：CAR-T細胞療法主要市場趨勢

  • CAR-T細胞療法市場促進因素
    • 市場促進因素的影響分析
  • CAR-T細胞療法市場限制因素
    • 市場限制因素的影響分析
  • CAR-T細胞療法市場機會
  • CAR-T細胞療法市場未來趨勢

第4章：CAR-T細胞療法產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景分析
  • 規範架構分析

第5章：CAR-T細胞療法市場：地緣政治緊張局勢升級的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：CAR-T細胞療法市場概況

  • CAR-T細胞療法市佔率分析，2024年
  • 主要製造商細分數據
    • 知名球員分析
    • 新興參與者分析

第7章：CAR-T細胞療法市場－依產品類型分類

  • 概述
    • 按產品類型分類的細分市場佔有率分析
    • 阿貝克瑪
    • 布雷揚齊
    • 卡維克蒂
    • 凱姆裡亞
    • 泰卡圖斯
    • 耶斯卡塔
    • 其他

第8章：CAR-T細胞療法市場－以標靶抗原分類

  • 概述
    • 按標靶抗原分類的細分市場佔有率分析
    • CD19
    • BCMA（B細胞成熟抗原）
    • CD22
    • GD2
    • HER2
    • GPC3
    • 其他（例如，EGFRvIII、CD7、CD123、間皮素）

第9章：CAR-T細胞療法市場－依適應症分類

  • 概述
    • 按指標分類的細分市場佔有率分析
    • 急性淋巴性白血病
    • 淋巴瘤
    • 多發骨髓瘤
    • 套細胞淋巴瘤

第10章：CAR-T細胞療法市場－以最終用戶分類

  • 概述
    • 按標靶抗原分類的細分市場佔有率分析
    • 醫院
    • 癌症治療中心
    • 其他

第11章：CAR-T細胞療法市場－依地域分類

  • 介紹
    • 按地域分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美CAR-T細胞療法主要生產商
    • 北美市場規模及預測（按國家/地區分類）
    • 北美市場規模及預測（依產品類型分類）
    • 北美市場規模及預測（以標靶抗原分類）
    • 北美市場規模及預測（依適應症分類）
    • 北美市場規模及預測（依最終用戶分類）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲CAR-T細胞療法主要生產商
    • 歐洲市場規模及預測（按國家/地區分類）
    • 歐洲市場規模及預測（依產品類型分類）
    • 歐洲市場規模及預測（以標靶抗原分類）
    • 歐洲市場規模及預測（依適應症分類）
    • 歐洲市場規模及預測（依最終用戶分類）
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 歐洲其他地區
  • 亞太地區
    • 概述
    • 亞太地區CAR T細胞療法主要生產商
    • 亞太市場規模及預測（依國家/地區分類）
    • 亞太市場規模及預測（依產品類型分類）
    • 亞太市場規模及預測（以標靶抗原分類）
    • 亞太地區市場規模及預測（依適應症分類）
    • 亞太市場規模及預測（依最終用戶分類）
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 亞太其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲CAR T細胞療法主要生產商
    • 拉丁美洲市場規模及預測（按國家/地區分類）
    • 拉丁美洲市場規模及預測（依產品類型分類）
    • 拉丁美洲市場規模及預測（以標靶抗原分類）
    • 拉丁美洲市場規模及預測（依適應症分類）
    • 拉丁美洲市場規模及預測（按最終用戶分類）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲（MEA）
    • 概述
    • 中東和非洲CAR T細胞療法主要生產商
    • MEA市場規模及預測（依國家/地區分類）
    • MEA市場規模及預測（依產品類型分類）
    • MEA市場規模及預測（以標靶抗原分類）
    • MEA市場規模及預測（依適應症分類）
    • MEA市場規模及預測（依最終用戶分類）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 中東和非洲其他地區

第12章：主要供應商分析－CAR-T細胞療法產業

  • 競爭基準化分析
    • Competitive Dashboard
    • Competitive Positioning
  • 公司簡介
    • XX
    • Others

第13章：360度AnalystView

第14章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV5762

CAR T-cell Therapy Market size was valued at US$ 5,678 Million in 2024, expanding at a CAGR of 38.5% from 2025 to 2032.

The CAR T-cell therapy involves engineered immune cell treatments that modify a patient's T cells which targets and then kills cancer cells, Specifically for certain blood cancers and is increasingly explored for solid tumors. The market is rapidly expanding due to robust clinical outcomes in relapsed or refractory hematologic malignancies, expanded research pipelines, increasing regulatory approvals, and increasing investment from biopharma and specialty cell therapy manufacturers. Complex manufacturing, the need for specialized treatment centers and High treatment costs, pose challenges, but manufacturing scale-up, partnerships and next-generation CAR designs are helping commercial expansion.

CAR T-cell Therapy Market- Market Dynamics

Improved Clinical Efficacy and Durable Remissions

CAR Tcell therapy has improved clinical efficacy and lasting remissions in patients with relapsed or refractory blood cancers. Strong results from clinical trials and real-world use have shown the treatment can produce long-term responses where other therapies failed, which encourages doctors to adopt it, motivates payers to cover the high costs, and attracts investment from pharmaceutical companies and manufacturers eager to expand indications and scale production.

CAR T-cell Therapy Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 38.5% over the forecast period (2025-2032)

Based on product type segmentation, Kymriah was predicted to show maximum market share in the year 2024

Based on target antigen segmentation, CD19 was the leading target antigen in 2024

Based on Indication segmentation, acute lymphoblastic leukemia was the leading indication segment in 2024

Based on end user segmentation, Cancer treatment centres was the leading indication segment in 2024

On the basis of region, North America was the leading revenue generator in 2024

CAR T-cell Therapy Market- Segmentation Analysis:

The Global CAR T-cell Therapy Market is segmented on the basis of Product Type, Target Antigen, Indication, End user, and Region.

The market is divided into seven categories based on product type: Abecma, Breyanzi, Carvykti, Kymriah, Tecartus, Yescarta and Others. The Established products like Kymriah and Yescarta lead the market at present because of earlier broader clinical experience, approvals, and larger commercial footprints.

For the Target Antigen the market is divided into again seven categories: CD19, BCMA (B-cell Maturation Antigen), CD22, GD2, HER2, GPC3 and Others (e.g., EGFRvIII, CD7, CD123, mesothelin). CD19 remains the dominant category in this segment today, driven by established success in B-cell leukemias and lymphomas. BCMA is the fastest growing category due to the strong responses in multiple myeloma and increasing product launches.

In By Indication segment there are four categories: Acute lymphoblastic leukemia, Lymphoma, Multiple Myeloma and Mantle Cell Lymphoma. Multiple myeloma represents the highest near-term upside due to multiple BCMA CARs entering the market. Solid tumors are the largest long-term opportunity but face substantial scientific and translational hurdles that will slow commercialization. Hematologic malignancies (acute lymphoblastic leukemia, various lymphomas, and multiple myeloma) will continue to drive near-term revenue and adoption because most approvals and clinician experience are concentrated here.

The End User segments includes Hospitals and specialized cancer treatment centers these are the primary sites of care because CAR T therapies need specialized infrastructure, inpatient monitoring, and multidisciplinary teams; these centers will capture the majority of current volume.

CAR T-cell Therapy Market- Geographical Insights

North America, particularly the United States, is the largest market due to strong biotech investment, established clinical trial infrastructure, and favorable reimbursement policies; Europe follows with growing adoption but variable national reimbursement landscapes; Asia-Pacific is a high-growth region driven by rising healthcare spending, expanding clinical capabilities in China, Japan, and South Korea, and increasing local manufacturing, though access and pricing remain barriers in some countries.

CAR T-cell Therapy Market- Competitive Landscape:

The competitive landscape is led by a mix of large biotech/pharma companies with approved CAR T products and numerous smaller innovators and academic spinouts developing next-generation and allogeneic therapies; competition centers on clinical performance, safety (reduced cytokine release syndrome/neurotoxicity), manufacturing scale and cost, and commercial partnerships for manufacturing and distribution, with M&A, licensing deals, and strategic alliances common as companies move to secure pipelines and production capacity.

Recent Developments:

On November 5, 2025, Prime Minister Narendra Modi unveiled three Indian innovations at ESTIC2025: QSIP, a 25-qubit QPU, and NexCAR19 - India's first indigenous CAR-T therapy by ImmunoACT. DBT and BIRAC supported development and funded a 200L GMP lentiviral production platform expected to serve about 1,000 patients a year. Ongoing DBT/BIRAC funding also supports wider CAR-T research for blood and solid tumors.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CAR T-CELL THERAPY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • ALLOGENE THERAPEUTICS
  • Aurora Biopharma
  • Bristol-Myers Squibb company
  • Cartesian Therapeutics, Inc.
  • Curocell Inc
  • Gilead Sciences
  • Johnson & Johnson Services, Inc.
  • JW Therapeutics
  • Lonza
  • Novartis
  • Others

GLOBAL CAR T-CELL THERAPY MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Abecma
  • Breyanzi
  • Carvykti
  • Kymriah
  • Tecartus
  • Yescarta
  • Others

GLOBAL CAR T-CELL THERAPY MARKET, BY TARGET ANTIGEN- MARKET ANALYSIS, 2019 - 2032

  • CD19
  • BCMA (B-cell Maturation Antigen)
  • CD22
  • GD2
  • HER2
  • GPC3
  • Others (e.g., EGFRvIII, CD7, CD123, mesothelin)

GLOBAL CAR T-CELL THERAPY MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Acute lymphoblastic leukemia
  • Lymphoma
  • Multiple Myeloma
  • Mantle Cell Lymphoma

GLOBAL CAR T-CELL THERAPY MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Cancer Treatment Centers
  • Others

GLOBAL CAR T-CELL THERAPY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. CAR T-cell Therapy Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. CAR T-cell Therapy Market Snippet by Product Type
    • 2.1.2. CAR T-cell Therapy Market Snippet by Target Antigen
    • 2.1.3. CAR T-cell Therapy Market Snippet by Indication
    • 2.1.4. CAR T-cell Therapy Market Snippet by End user
    • 2.1.5. CAR T-cell Therapy Market Snippet by Country
    • 2.1.6. CAR T-cell Therapy Market Snippet by Region
  • 2.2. Competitive Insights

3. CAR T-cell Therapy Key Market Trends

  • 3.1. CAR T-cell Therapy Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. CAR T-cell Therapy Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. CAR T-cell Therapy Market Opportunities
  • 3.4. CAR T-cell Therapy Market Future Trends

4. CAR T-cell Therapy Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. CAR T-cell Therapy Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. CAR T-cell Therapy Market Landscape

  • 6.1. CAR T-cell Therapy Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. CAR T-cell Therapy Market - By Product Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product Type, 2024 & 2032 (%)
    • 7.1.2. Abecma
    • 7.1.3. Breyanzi
    • 7.1.4. Carvykti
    • 7.1.5. Kymriah
    • 7.1.6. Tecartus
    • 7.1.7. Yescarta
    • 7.1.8. Others

8. CAR T-cell Therapy Market - By Target Antigen

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Target Antigen, 2024 & 2032 (%)
    • 8.1.2. CD19
    • 8.1.3. BCMA (B-cell Maturation Antigen)
    • 8.1.4. CD22
    • 8.1.5. GD2
    • 8.1.6. HER2
    • 8.1.7. GPC3
    • 8.1.8. Others (e.g., EGFRvIII, CD7, CD123, mesothelin)

9. CAR T-cell Therapy Market - By Indication

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
    • 9.1.2. Acute lymphoblastic leukemia
    • 9.1.3. Lymphoma
    • 9.1.4. Multiple Myeloma
    • 9.1.5. Mantle Cell Lymphoma

10. CAR T-cell Therapy Market - By End user

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Target Antigen, 2024 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Cancer Treatment Centers
    • 10.1.4. Others

11. CAR T-cell Therapy Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. CAR T-cell Therapy Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. CAR T-cell Therapy Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. CAR T-cell Therapy Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. CAR T-cell Therapy Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. CAR T-cell Therapy Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- CAR T-cell Therapy Industry

  • 12.1. Competitive Benchmarking
    • 12.1.1. Competitive Dashboard
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. XX
    • 12.2.2. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us